GILD icon

Gilead Sciences

96.04 USD
-2.00
2.04%
At close Feb 7, 4:00 PM EST
Pre-market
95.48
-0.56
0.58%
1 day
-2.04%
5 days
-1.02%
1 month
5.97%
3 months
-1.90%
6 months
29.78%
Year to date
4.53%
1 year
29.05%
5 years
39.45%
10 years
-0.89%
 

About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Employees: 18,000

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 10 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

47% more first-time investments, than exits

New positions opened: 168 | Existing positions closed: 114

38% more funds holding in top 10

Funds holding in top 10: 13 [Q2] → 18 (+5) [Q3]

18% more capital invested

Capital invested by funds: $73.5B [Q2] → $86.5B (+$12.9B) [Q3]

2% more funds holding

Funds holding: 1,648 [Q2] → 1,682 (+34) [Q3]

3% more call options, than puts

Call options by funds: $965M | Put options by funds: $941M

10% less repeat investments, than reductions

Existing positions increased: 615 | Existing positions reduced: 683

2.42% less ownership

Funds ownership: 85.31% [Q2] → 82.89% (-2.42%) [Q3]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$80
17%
downside
Avg. target
$105
9%
upside
High target
$125
30%
upside

10 analyst ratings

positive
70%
neutral
30%
negative
0%
RBC Capital
Brian Abrahams
16% 1-year accuracy
12 / 76 met price target
13%downside
$84
Sector Perform
Reiterated
3 Feb 2025
JP Morgan
Chris Schott
53% 1-year accuracy
9 / 17 met price target
20%upside
$115
Overweight
Maintained
29 Jan 2025
Morgan Stanley
Matthew Harrison
53% 1-year accuracy
10 / 19 met price target
18%upside
$113
Overweight
Upgraded
10 Jan 2025
Cantor Fitzgerald
Olivia Brayer
45% 1-year accuracy
10 / 22 met price target
17%downside
$80
Neutral
Reiterated
11 Dec 2024
B of A Securities
Tim Anderson
75% 1-year accuracy
6 / 8 met price target
13%upside
$109
Buy
Reinstated
10 Dec 2024

Financial journalist opinion

Based on 37 articles about GILD published over the past 30 days

Neutral
Zacks Investment Research
2 hours ago
The Zacks Analyst Blog Uber, Comcast, Gilead Sciences and Onfolio Holdings
Uber, Comcast, Gilead Sciences and Onfolio Holdings are included in this Analyst Blog.
The Zacks Analyst Blog Uber, Comcast, Gilead Sciences and Onfolio Holdings
Positive
The Motley Fool
16 hours ago
3 Fabulous Dividend Stocks to Buy in February
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month.
3 Fabulous Dividend Stocks to Buy in February
Positive
The Motley Fool
1 day ago
These 2 Dividend Stocks Are Absolute Bargains Right Now
Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time likely has a strong underlying business. It's even better to invest in excellent income stocks when they seem to be trading at attractive valuations, which isn't always easy to find since such corporations are in high demand.
These 2 Dividend Stocks Are Absolute Bargains Right Now
Neutral
Zacks Investment Research
2 days ago
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports fourth-quarter 2024 results.
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Neutral
Business Wire
2 days ago
KBRA Assigns Preliminary Ratings to Gilead 2025-1 Aviation Limited
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to the Series A Notes and Series B Notes issued by Gilead 2025-1 Aviation Limited and Gilead Aviation (Warehouse) LLC, an aviation ABS transaction (together, Ghost 2025-1). Ghost 2025-1 represents the sixth aviation ABS transaction serviced by wholly owned subsidiaries of AerCap Holdings N.V. (AerCap). As of September 30, 2024, AerCap and its subsidiaries had total assets of approximately $74 billion and had a fleet (owned or serviced).
KBRA Assigns Preliminary Ratings to Gilead 2025-1 Aviation Limited
Positive
Zacks Investment Research
3 days ago
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Gilead (GILD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Positive
The Motley Fool
3 days ago
3 Top AI-Powered Biotech Stocks to Buy in February
Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-changer for the next generation of innovation.
3 Top AI-Powered Biotech Stocks to Buy in February
Positive
Zacks Investment Research
4 days ago
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
Gilead Sciences (GILD) closed at $99.65 in the latest trading session, marking a +1.69% move from the prior day.
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
Neutral
CNBC Television
4 days ago
Final Trade: UBER, MP, MGNI, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: UBER, MP, MGNI, GILD
Positive
Zacks Investment Research
5 days ago
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Charts implemented using Lightweight Charts™